Skip to content
Screener

Pfizer PFE Q2 2026 earnings

Reported August 4, 2026 · Before market open

Revenue$15.0BBeat by $634.6M
Adjusted EPS$0.77Beat by $0.09
Revenue estimate$14.4B
EPS estimate$0.68

Earnings data and commentary were extracted with AI from company filings and may contain errors. Verify important details in the filing.

Next report

Nov 3, 2026 (in a month)
Revenue estimate$15.9B
EPS estimate$0.77

Financials

Q2 2026

Income statement

See full
Revenue$15.0B+2.6%
Gross profit$10.9B+0.6%
Net income-$248.0M-109%
EPS (diluted)-$0.04-108%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$160.27B+4.1%
Enterprise value$222.94B—
P/E18×—
P/S2.5×+0.1×

Profitability

See full
Gross margin73.2%+1.1pp

Segments

By product

See full
Eliquis$2.4B+21.1%
Vyndaqel family$1.8B+9.1%
Ibrance$1.1B+0.9%
All Other Hospital and Biosimilars$952.0M—
All other Primary Care$699.0M-5.0%

By segment

See full
Biopharma$14.7B+2.5%

FAQ

When did Pfizer report Q2 2026 earnings?
Pfizer (PFE) reported Q2 2026 earnings on August 4, 2026 before market open.
What were Pfizer's Q2 2026 revenue and EPS?
Pfizer reported revenue of $15.0B and adjusted eps of $0.77 for Q2 2026.
Did Pfizer beat estimates in Q2 2026?
Revenue beat the consensus estimate of $14.4B by $634.6M. EPS beat the consensus estimate of $0.68 by $0.09.
How did Pfizer's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2.6% from $14.7B a year earlier.
Where can I find Pfizer's Q2 2026 SEC filings?
You can read the 8-K earnings release (0000078003-26-000094) and the 10-Q periodic report (0000078003-26-000095) directly on SEC EDGAR. The filing index links above go to sec.gov.